Clinical trials: KRAS p.G12C Mutant Advanced Solid Tumors
Advanced Solid Tumors
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
This is an open-label, single-arm, multicenter, Phase 1 study of LY3537982 as monotherapy in Chinese participants with KRAS G12C-mutant advanced solid tumors.
- Trial name
- NCT06235983
- Testing
- LY3537982
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
KRAS p.G12C Mutant Advanced Solid Tumors
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS…
- Trial name
- NCT03600883
- Testing
- sotorasib, Anti PD-1/L1, Midazolam
- Where
- 133 sites in United States, Australia and 14 more
- Volunteers
- 713 people
- Sponsor
- Amgen
KRAS G12C Mutation, KRAS G12S Mutation
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365.
- Conditions
- KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
- Trial name
- NCT06720987
- Testing
- KQB365, Cetuximab, KQB198
- Where
- 11 sites in United States
- Volunteers
- 140 people
- Sponsor
- Kumquat Biosciences Inc.
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C…
- Trial name
- NCT06435455
- Testing
- GH21, D-1553
- Volunteers
- 126 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.